How Is Breast Cancer Diagnosed and Treated?

TL;DR

Breast cancer is diagnosed through symptom-based imaging and core needle biopsy, then treated according to pathology, receptor status, lymph node involvement, and TNM stage. Symptomatic patients younger than 30 generally receive ultrasound first, while those 30 or older receive diagnostic mammography followed by targeted ultrasound. Read on to understand suspicious clinical features, BI-RADS results, biopsy decisions, cancer subtypes, and treatment options.

Transcript

welcome back to the ninja nerd podcast today we've got a brand new episode for you on breast cancer we're finally moving on we're out of hee I know how long were we in that about seven years seven years it seemed like that right definitely was a while so it's nice to move into a new topic oncology is a big big topic filled with lots of different th... Read More

Key Insights

• A firm, irregular, non-tender breast mass accompanied by nipple retraction and axillary lymph node enlargement is concerning for breast cancer. Upper outer quadrant location and increasing breast asymmetry add to the suspicion, although definitive diagnosis still requires imaging and tissue analysis.
• Nipple retraction can result from a breast mass tethering and shortening the Cooper suspensory ligaments. This process can pull the nipple or nearby skin inward, making retraction an ominous clinical feature when it appears alongside a firm, irregular breast lesion.
• A family history combining breast cancer and ovarian cancer raises suspicion for a BRCA mutation. BRCA1 and BRCA2 mutations are important inherited risk factors, and BRCA1 is particularly associated in the discussion with increased risks of both breast and ovarian cancer.
• Diagnostic imaging differs from screening because symptomatic patients require evaluation of a specific abnormality. Breast ultrasound is generally used first below age 30, while patients age 30 or older typically receive diagnostic mammography followed by targeted breast ultrasound.
• The BI-RADS score communicates how breast imaging should be managed. Scores of 1 and 2 indicate normal or benign findings, 3 generally prompts closer imaging follow-up in 6–12 months, and scores of 4 or higher indicate a suspicious lesion requiring biopsy.
• Core needle biopsy is the preferred method for evaluating a suspicious solid breast mass. It obtains enough tissue to determine whether cancer is present, identify the histologic type, and perform immunohistochemistry for clinically important markers such as ER, PR, and HER2.
• Invasive breast carcinoma has crossed the basement membrane, unlike ductal or lobular carcinoma in situ. Invasive ductal carcinoma accounts for 70–80% of invasive breast cancers, while invasive lobular carcinoma represents a smaller proportion in the discussion.
• Breast cancer treatment is guided by molecular subtype, pathology, prognostic factors, and TNM staging. Available strategies discussed include surgery, radiation, endocrine therapy for hormone receptor-positive disease, trastuzumab for HER2-positive disease, chemotherapy, and immunotherapy for triple-negative disease.

Questions & Answers

Q: How is breast cancer diagnosed and treated?

Diagnosis begins with diagnostic imaging of a symptomatic abnormality, followed by core needle biopsy when findings are suspicious. Pathology, ER, PR, and HER2 status, lymph node involvement, prognostic factors, and TNM staging then guide surgery, radiation, endocrine therapy, HER2-targeted therapy, chemotherapy, or immunotherapy.

Q: What breast lump features suggest breast cancer?

Concerning features include a firm, irregular, non-tender mass, nipple retraction, increasing breast asymmetry, and an enlarged axillary lymph node. An upper outer quadrant location and a family history involving breast and ovarian cancer further raise suspicion, but imaging and tissue analysis are required for diagnosis.

Q: Why can breast cancer cause nipple retraction?

A breast mass can tether to the Cooper suspensory ligaments and shorten them. This may pull the nipple or nearby skin inward, making new retraction especially concerning when accompanied by a firm, irregular mass.

Q: When are breast ultrasound and diagnostic mammography used?

A symptomatic patient younger than 30 generally receives breast ultrasound first. A symptomatic patient age 30 or older usually receives diagnostic mammography followed by targeted ultrasound, while screening imaging is intended for patients without symptoms.

Q: What does a BI-RADS score mean?

BI-RADS communicates breast-imaging findings and their recommended management. Scores of 1 and 2 indicate normal or benign findings, 3 generally prompts closer imaging follow-up in 6–12 months, and 4 or higher indicates a suspicious lesion requiring biopsy.

Q: Why is core needle biopsy used for a suspicious breast mass?

Core needle biopsy obtains enough tissue to determine whether a suspicious lesion is malignant and identify its histologic type. The sample also supports immunohistochemistry for clinically important markers such as ER, PR, and HER2.

Q: What is invasive ductal carcinoma?

Invasive ductal carcinoma begins in ductal tissue and has crossed the basement membrane into surrounding tissue. It accounts for 70–80% of invasive breast cancers, whereas ductal carcinoma in situ remains confined within the ducts.

Q: How does receptor status affect breast cancer treatment?

ER-positive or PR-positive disease can be treated with endocrine therapy, while HER2-positive disease can receive HER2-targeted treatment such as trastuzumab. Triple-negative disease lacks those targets, so chemotherapy and immunotherapy are important strategies alongside appropriate surgery and radiation.

Summary & Key Takeaways

• Breast cancer evaluation begins by distinguishing symptomatic diagnosis from routine screening. Concerning findings include a firm, irregular, non-tender mass, nipple retraction, breast asymmetry, and axillary lymph node enlargement. Family histories involving breast and ovarian cancer can also raise concern for inherited BRCA1 or BRCA2 mutations.

• For symptomatic patients younger than 30, breast ultrasound is generally the initial imaging test. Patients age 30 or older usually receive diagnostic mammography followed by targeted ultrasound. Spiculated architecture, microcalcifications, and an irregular hypoechoic mass are suspicious findings that warrant tissue sampling rather than routine imaging follow-up.

• Core needle biopsy confirms whether a suspicious lesion is malignant and supplies tissue for histology and immunohistochemistry. Invasive ductal carcinoma is the most common invasive breast cancer. ER, PR, and HER2 findings, together with TNM staging and prognostic factors, guide endocrine therapy, HER2-targeted treatment, chemotherapy, immunotherapy, surgery, and radiation.